FDA records identify FUJIFILM Healthcare Americas Corporation as the applicant behind Synapse PACS, a medical image management and processing system regulated under 21 CFR 892.2050 in Class II. The documented record spans a substantial-equivalence clearance for version 7.5 and a separate recall of version 7.4.310, giving industry readers a view of both the regulatory pathway and post-market activity for the same software family. [1][4][8]
The applicant and its documented product
The 510(k) decision letter for K243647 is addressed to FUJIFILM Healthcare Americas Corporation at 81 Hartwell Ave Suite 300, Lexington, Massachusetts, and names Synapse PACS (7.5) as the trade/device name. The letter lists regulation number 21 CFR 892.2050, regulation name Medical Image Management And Processing System, regulatory class Class II, and product code QIH. The submission is dated and received June 3, 2025. [4]
The company's own product pages describe Synapse Radiology PACS as uniting radiology, mammography, cardiology, pathology, and specialty department imaging on one diagnostic viewer, and position it as the foundation of Synapse Enterprise PACS. Those pages also describe Synapse Enterprise PACS as a cloud and AI-enabled enterprise system with Synapse Viewer eXtension and Synapse Cloud hosting. These are publisher-stated product descriptions, not independently verified performance claims. [6][8]
Clearance scope for Synapse PACS 7.5
The K243647 letter states that comparison with Synapse 3D (K221677, reference device) showed the improved algorithm does not affect the safety or efficacy of Synapse PACS 7.5.0, and it points to performance bench testing for the improved algorithm. The same document notes that MIP, MPR Fusion, and volume rendering are not intended for mammography use. [4]
Recall Z-3030-2026 for version 7.4.310
A separate FDA enforcement record, recall number Z-3030-2026, covers FUJIFILM Synapse PACS software v7.4.310, described as a radiological image processing system. The recalling firm is FUJIFILM Healthcare Americas Corporation, the classification is Class II, and the status is Ongoing. The stated reason for recall is a software issue that may cause the ruler measurement to be inaccurate. [1]
That record lists six units, a voluntary firm-initiated action, recall initiation on July 22, 2026, and center classification on August 26, 2026, with initial firm notification by letter. Distribution is described as worldwide, with US nationwide distribution in New York, Virginia, Kansas, Oregon, and Ohio, plus Australia. The listed code information includes UDI (01)00854904006008(10)0704310 and serial numbers. [1]
Corporate context and limits of the record
FUJIFILM Holdings America Corporation's affiliate page lists Fujifilm Healthcare Americas Corporation as a provider of diagnostic imaging products and medical information solutions, with a Lexington, Massachusetts address and a listed telephone number. That page establishes a group relationship; it does not establish ownership terms beyond the listing, and the FDA filing address is not treated here as a headquarters determination. [7]
The supplied portfolio snapshot reports zero linked records and no decision counts, so no collection-level clearance or recall ratios can be stated. The recall sample contains a single entry, Z-3030-2026. Additional Synapse recall pages appear in the sources only as database navigation text without substantive recall details, so no further recall specifics are asserted. [1][2][9]





